Centro Nacional de Biotecnología (CNB-CSIC)

National Biotechnology Centre (CNB-CSIC)

Information
C/ Darwin nº 3, Campus de Cantoblanco 28049 Madrid

cancer, covid-19, gene editing, rare diseases, immunology, microbiology, nanoscience, AIDS / HIV, transgenics
Contact
Susana de Lucas
Communication and scientific dissemination
divulgacion@cnb.csic.es
91 585 48 42

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Co-director of the Microbiome Analysis Laboratory and Research Professor

Co-director of the coronavirus group at the National Biotechnology Centre (CNB-CSIC)

Research professor at the National Biotechnology Centre (CNB-CSIC) and at the CIBERER-ISCIII

 

CNB-CSIC scientific researcher at the Instituto de Investigación Sanitaria de Santiago de Compostela, IDIS

Virologist at the National Center for Biotechnology (CNB-CSIC)

Researcher at the National Biotechnology Centre (CNB-CSIC)

Researcher specialized in ecology and evolution of antibiotic resistance.

Virologist at the National Biotechnology Centre (CNB-CSIC)

Contents related to this centre
brain

A US team has successfully integrated brain-like tissue derived from human stem cells into the brains of newborn rats. The research is published in the journal Nature.

Vacuna

To estimate the effectiveness of two or three doses of vaccines against covid-19 infection and hospitalisation, researchers in Denmark conducted a study of all previously uninfected Danish residents aged 12 years and older. The conclusion of the research, which is published in PLOS Medicine, is that a third dose provided greater protection against infection and hospitalisation with omicron than two vaccines.

Congreso

The extraordinary plenary session of the Congress of Deputies today approved the reform of the Law on Science, Technology and Innovation. After being passed in the Lower House without any votes against it on 23 June, the bill was approved in the Senate on 20 July with an amendment referring to indefinite-term contracts, which was rejected today in Congress. 

embryos

Research published in Nature shows the creation of synthetic mouse embryos derived from stem cells. The embryo model copies the stages of natural rodent embryo development that take place up to day 8.5 after fertilisation and includes regions of the brain, a neural tube and a structure similar to a beating heart.

Bulldog inglés

The variety of current dog breeds is the product of two centuries of human intervention, which has often selected characters for extravagance or supposed aesthetics. Lluís Montoliu, president of the CSIC Ethics Committee until last February, recalls that 15% of current dog breeds have some sort of more or less serious congenital disease.

 

vacuna

The Minister of Health, Carolina Darias, announced in an interview on La Sexta that there will be a fourth dose of the covid-19 vaccine "for the entire population".

Vacuna

In a press release published this week, Moderna has shared the first data on its new bivalent adapted vaccine against Omicron.

asintomáticos

A review with meta-analysis published in the journal PLoS Medicine concludes that the percentage of asymptomatic people with covid-19 is lower, and that they are less contagious than those who are pre-symptomatic or symptomatic.

viruela de los monos

On 18 May, the Ministry of Health confirmed to SMC Spain that eight suspected cases "clinically compatible" with monkeypox had been detected. The same afternoon, the Consejería de Sanidad de la Comunidad de Madrid reported that it had detected 23 possible cases of infection. These cases need to be confirmed after testing. At least 7 cases have been confirmed in the UK and Portugal. This is a rare zoonotic viral disease and there is no vaccine or specific treatment available. Treatment is symptomatic and supportive. Most cases are resolved favourably.

Vacunas covid.

The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) consider it too early for the general population to receive a fourth dose of covid-19 mRNA vaccines. Both agencies do agree that people over 80 years of age should receive it because of their increased risk of severe disease.